DANONE (BSN.DE) Stock Fundamental Analysis
Europe • Frankfurt Stock Exchange • FRA:BSN • FR0000120644
66.2 EUR
-0.32 (-0.48%)
Last: Jan 29, 2026, 07:00 PM
Overall BSN gets a fundamental rating of 5 out of 10. We evaluated BSN against 62 industry peers in the Food Products industry. While BSN has a great profitability rating, there are quite some concerns on its financial health. BSN is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
- BSN had positive earnings in the past year.
- In the past year BSN had a positive cash flow from operations.
- Each year in the past 5 years BSN has been profitable.
- BSN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- BSN has a better Return On Assets (4.20%) than 62.90% of its industry peers.
- Looking at the Return On Equity, with a value of 11.59%, BSN is in the better half of the industry, outperforming 66.13% of the companies in the same industry.
- BSN has a better Return On Invested Capital (6.83%) than 62.90% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for BSN is in line with the industry average of 7.38%.
- The 3 year average ROIC (6.38%) for BSN is below the current ROIC(6.83%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.2% | ||
| ROE | 11.59% | ||
| ROIC | 6.83% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
1.3 Margins
- The Profit Margin of BSN (6.72%) is better than 72.58% of its industry peers.
- BSN's Profit Margin has been stable in the last couple of years.
- BSN's Operating Margin of 13.25% is fine compared to the rest of the industry. BSN outperforms 77.42% of its industry peers.
- BSN's Operating Margin has declined in the last couple of years.
- BSN has a Gross Margin of 50.47%. This is amongst the best in the industry. BSN outperforms 82.26% of its industry peers.
- In the last couple of years the Gross Margin of BSN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.25% | ||
| PM (TTM) | 6.72% | ||
| GM | 50.47% |
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BSN is still creating some value.
- Compared to 1 year ago, BSN has more shares outstanding
- BSN has less shares outstanding than it did 5 years ago.
- Compared to 1 year ago, BSN has an improved debt to assets ratio.
2.2 Solvency
- BSN has an Altman-Z score of 2.38. This is not the best score and indicates that BSN is in the grey zone with still only limited risk for bankruptcy at the moment.
- BSN has a Altman-Z score of 2.38. This is comparable to the rest of the industry: BSN outperforms 59.68% of its industry peers.
- The Debt to FCF ratio of BSN is 5.07, which is a neutral value as it means it would take BSN, 5.07 years of fcf income to pay off all of its debts.
- BSN has a better Debt to FCF ratio (5.07) than 69.35% of its industry peers.
- BSN has a Debt/Equity ratio of 0.83. This is a neutral value indicating BSN is somewhat dependend on debt financing.
- The Debt to Equity ratio of BSN (0.83) is worse than 69.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 5.07 | ||
| Altman-Z | 2.38 |
ROIC/WACC1.08
WACC6.34%
2.3 Liquidity
- BSN has a Current Ratio of 0.95. This is a bad value and indicates that BSN is not financially healthy enough and could expect problems in meeting its short term obligations.
- BSN has a worse Current ratio (0.95) than 69.35% of its industry peers.
- A Quick Ratio of 0.78 indicates that BSN may have some problems paying its short term obligations.
- BSN's Quick ratio of 0.78 is in line compared to the rest of the industry. BSN outperforms 45.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.78 |
3. Growth
3.1 Past
- The Earnings Per Share has been growing slightly by 4.47% over the past year.
- The Earnings Per Share has been decreasing by -1.17% on average over the past years.
- BSN shows a small growth in Revenue. In the last year, the Revenue has grown by 0.54%.
- Measured over the past years, BSN shows a small growth in Revenue. The Revenue has been growing by 1.60% on average per year.
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%
3.2 Future
- Based on estimates for the next years, BSN will show a small growth in Earnings Per Share. The EPS will grow by 6.09% on average per year.
- The Revenue is expected to grow by 2.86% on average over the next years.
EPS Next Y7.53%
EPS Next 2Y7.18%
EPS Next 3Y7.53%
EPS Next 5Y6.09%
Revenue Next Year0.7%
Revenue Next 2Y1.88%
Revenue Next 3Y2.56%
Revenue Next 5Y2.86%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 17.70, BSN is valued on the expensive side.
- BSN's Price/Earnings is on the same level as the industry average.
- BSN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 28.39.
- BSN is valuated correctly with a Price/Forward Earnings ratio of 15.88.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of BSN is on the same level as its industry peers.
- BSN is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 25.72, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.7 | ||
| Fwd PE | 15.88 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BSN is on the same level as its industry peers.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of BSN indicates a somewhat cheap valuation: BSN is cheaper than 66.13% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.72 | ||
| EV/EBITDA | 9.55 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BSN does not grow enough to justify the current Price/Earnings ratio.
- BSN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.35
PEG (5Y)N/A
EPS Next 2Y7.18%
EPS Next 3Y7.53%
5. Dividend
5.1 Amount
- BSN has a Yearly Dividend Yield of 3.15%.
- Compared to an average industry Dividend Yield of 2.38, BSN pays a bit more dividend than its industry peers.
- Compared to an average S&P500 Dividend Yield of 1.82, BSN pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.15% |
5.2 History
- The dividend of BSN has a limited annual growth rate of 1.58%.
Dividend Growth(5Y)1.58%
Div Incr Years3
Div Non Decr Years4
5.3 Sustainability
- 74.99% of the earnings are spent on dividend by BSN. This is not a sustainable payout ratio.
- BSN's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP74.99%
EPS Next 2Y7.18%
EPS Next 3Y7.53%
DANONE / BSN.DE FAQ
What is the fundamental rating for BSN stock?
ChartMill assigns a fundamental rating of 5 / 10 to BSN.DE.
What is the valuation status for BSN stock?
ChartMill assigns a valuation rating of 4 / 10 to DANONE (BSN.DE). This can be considered as Fairly Valued.
How profitable is DANONE (BSN.DE) stock?
DANONE (BSN.DE) has a profitability rating of 7 / 10.
What is the earnings growth outlook for DANONE?
The Earnings per Share (EPS) of DANONE (BSN.DE) is expected to grow by 7.53% in the next year.
Is the dividend of DANONE sustainable?
The dividend rating of DANONE (BSN.DE) is 6 / 10 and the dividend payout ratio is 74.99%.